Development of any cancer reflects a progressive accumulation of alterations in various genes. Oncogenes, tumour suppressor genes, DNA repair genes and metastasis suppressor genes have been investigated in prostate cancer. Here, we review current understanding of the molecular biology of prostate cancer. Detailed understanding of the molecular basis of prostate cancer will provide insights into the aetiology and prognosis of the disease, and suggest avenues for therapeutic intervention in the future.
Introduction
The notion that neoplasia may be attributable to discrete genetic elements was first supported experimentally in 1911 when Rous 1, 2 reported that sarcoma in chickens could be induced by cell-free filtrates. Decades later retroviruses were discovered. A unique transforming viral oncogene, v-src (viral-avian sarcoma oncogene) was found to be responsible for Rous sarcoma. 3, 4 Many other viral oncogenes have been discovered since and homologous cellular genes exist in many higher species, including man. 5 For example, the human homologue of v-src is C-SRC, which is located at chromosome 20q12-13 and encodes an important cell-signalling protein. 3, 4 These viral-related DNA sequences in higher organisms generally code for proteins important in cell growth control. 6 These normal gene sequences were termed 'proto-oncogenes' and their altered counterparts were termed 'oncogenes'. By the mid-1970s, the concept of dominant 'cancer genes' that is, oncogenes, as predicted by Huebner and Todaro 5 in 1969, had received a good deal of experimental support.
Development of any neoplasm reflects a progressive and cumulative alteration in various genes. Oncogenes function in a dominant mode, whereas tumour suppressor genes (TSGs) are recessive. Mutations in the genes encoding DNA repair proteins can result in the accumulation of DNA replication errors leading to acceleration in the rate of carcinogenesis. Loss of function of metastasis suppressor genes increases the metastatic potential of a cancer as it develops.
Genomewide linkage analysis and loss of heterozygosity (LOH) studies have identified 1p36, 1q24-q25, 1q42.2-43, 7p22, 8p22, 10q23.31, 10q25, 11p11.2, 13q12.3, 17p11, Xq11-q12 and Xq27-q28 (Table 1) as potential prostate cancer (PC) susceptibility loci. 7 Further advances will require the analysis of hundreds of PC probands and their families to establish the relative importance of genetic variants at all these loci. The emergence of new resources has generated new optimism. Among these new tools are the entire human genome sequence and the possibility that soon the entire complement of human genes will be known and the functions of most of their protein products elucidated. 8 The search for susceptibility loci is being facilitated by comprehensive single nucleotide polymorphism (SNP) maps 9,10 and by haplotype mapping, which tracks the distribution of clusters of SNPs in linkage disequilibrium, that segregate together. 11 Together with high throughput DNA sequencing and microarrays for whole genome expression scanning, 12 advances in proteomics are another cause for optimism. The development of the above molecular tools along with bioinformatics for analysing sequence and association data, will greatly accelerate the search for the genetic basis of most malignancies. The Cancer Genome Project 13 will identify previously unexpected molecular changes in malignancy and will provide molecular targets for the development of new therapies. 14 
Oncogenes
Proto-oncogenes participate in normal cell proliferation, encoding a variety of proteins that function as growth factors, growth factor receptors, regulators of replication or transcription, modifiers of protein function or in other signalling pathways (Table 2) . 15 Obviously, alterations to these critical processes can cause aberrant growth and contribute to neoplastic transformation (Table 3) . Proto-oncogenes can be activated by a variety of mechanisms including insertional mutagenesis, amplification, point mutation and translocation. 16, 17 The presence of an altered oncogene is tumorigenic despite one normal allele, as they function in a dominant manner. 6 The paradigm for mutational oncogene activation is K-RAS (originally named after a rat sarcoma). Single base substitutions at three sites in the coding sequence convert K-RAS to an oncogene. 18, 19 This gene has been widely studied in human tumours, including urological neoplasms. 20 Gene amplification generates extra copies of a normal proto-oncogene. Protein overexpression is oncogenic, even in the absence of point mutations. Examples of this mechanism include N-MYC in neuroblastoma 21 and C-ERB-B2 (avian erythroblastosis virus oncogene B2 at 17p12, also called HER-2 or NEU) in breast cancer. 22 Copy number and corresponding protein levels correlate with adverse outcomes in both of these cancers. 21, 23 With translocations, the oncogene is moved so that the normal sequence comes under the control of different upstream promotors and this inappropriate expression may be oncogenic. 24 The paradigm for this phenomenon is the c-ABL/BCR translocation. 25 In chronic myeloid leukaemia (CML), the Philadelphia chromosome 26 arises when the C-ABL gene transfers from chromosome 9 to the breakpoint cluster region (BCR) of chromosome 22, creating a fusion gene BCR-ABL that is oncogenic. 27 Translocations/rearrangements are also important in the pathogenesis of other leukaemias and lymphomas. In Burkitt's lymphoma the C-MYC proto-oncogene from chromosome 8 is placed under control of the immunoglobulin heavy chain promoter on chromosome 14.
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CML provides the first compelling case where understanding of pathological mechanism at the molecular level has led to the development of a new drug, the BCR/ABL kinase inhibitor, imatinib. 29, 30 
Oncogenes in prostate cancer
No oncogene has been linked conclusively with the initiation or early progression of PC. 15 .
In addition to the classic oncogenes, a plethora of biological markers have also received some study in PC, including morphometric markers, proliferation markers, neuroendocrine markers, cytokeratins, lectins, mucins, stromal factors and even blood group antigens. 31 Growth factors themselves have been extensively studied in PC. 32 Although not among the recognised oncogenes, if the protein is over-active and contributes to prostate carcinogenesis, or metastasis, it could be termed a prostate-specific 'oncogene'.
RAS oncogenes
Of the oncogenes, the RAS gene family (Harvey (H), Kirsten (K) and neuroblastoma (N) RAS), have been most widely studied in PC. 15 RAS genes encode cytoplasmic 21 kDa GTPase signal transduction molecules. The protein is localised to the inner leaflet of the plasma membrane, by farnesylation. 33 The RAS oncogenes are activated by missense point mutations at codon 12, 13 or 61.
18,34 Altered p21 proteins stimulate cell proliferation even in the absence of external signals. 19 They do not function correctly as GTPases and by maintaining their activated GTP-bound state they have constitutive signal transmission capability. 34 The diagnostic assessment of RAS proteins in PC has not yielded clinically useful prognostic information. 33, 35, 36 RAS mutations were relatively uncommon in PC in the United States with no prognostic utility. [37] [38] [39] Interestingly, there appear to be racial variations in RAS mutation rates, as well as differences between clinicallydetected and autopsy PC cases. In cases from Japan, in both incidentally discovered and advanced PC, about 25% appear to harbour RAS mutations. [40] [41] [42] The clinical implications of these results are unclear.
The C-MYC oncogene
The MYC family of oncogenes, in particular C-MYC, has also received attention in PC. 43 This transcription factor is involved in differentiation and the level of C-MYC mRNA is higher in proliferating cells. 44 Levels fall dramatically when cells withdraw from the cell cycle or undergo terminal differentiation. 44 A gene that is involved in these cellular processes might be involved in tumourigenesis if its function is altered, particularly by amplification. A number of studies have shown that C-MYC mRNA is elevated in PC, compared to BPH or normal prostate tissue, and there tends to be enhanced expression with higher-grade tumours. 45 On the other hand, a study utilising in situ hybridisation, in which C-MYC expression could be examined in tissue sections rather than in homogenised tissue extracts, did not find c-myc overexpression in PC. 46 The C-MYC gene itself does not appear to be amplified in prostate tumours, 37, 45 although C-MYC amplification occurs in some PC cell lines. 47 , 48 Fox et al 49, 50 utilised the C-MYC protein product as a clinical prognostic marker in localised PC. Approximately 70% of PCs and BPH samples express C-MYC protein. Given this C-MYC expression in BPH, it is not suppressing that there was no correlation of this with survival.
The C-ERB-B2 oncogene C-ERB-B2 (NEU, HER-2) (17q11. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . homologue was initially identified in 1981, in a rat glioblastoma. 51 It codes for a protein that is similar (but not identical) to the epidermal growth factor receptor. 52 Two groups found C-ERB-B2 amplification in human tumour tissues. 53, 54 The most common mechanism of C-ERB-B2 activation in human neoplasms is amplification, which almost always results in overproduction of C-ERB-B2 mRNA. 55 Amplification of C-ERB-B2 has been found in a significant number of cell lines derived from human breast adenocarcinomas but rarely from other tissues. [56] [57] [58] Although the C-ERB-B2 oncogene has been studied in PC, its clinical utility as a tumour marker or therapeutic target remains unclear. Unlike in breast cancer, C-ERB-B2 is not frequently amplified in PC. Increased C-ERB-B2 copy number appears to be rare in clinically localised PC, 59 but C-ERB-B2 overexpression has been reported in up to 60% of patients with hormone-refractory PC. This correlated with shortened survival. 60 High C-ERB-B2 expression is associated with anti-androgen therapy and may contribute to androgen-independence in PC. 61 Sadasivan et al 62 found that C-ERB-B2 expression correlated with advanced stages and higher Gleason scores. Conversely Kuhn et al 63 in a preliminary study of 53 radical prostatectomy (RP) cases, found that C-ERB-B2 protein expression did not predict serological or clinical recurrence. Savinainen et al 64 found that the expression of C-ERB-B2 in PC was relatively low and was not altered during disease progression.
Veltri et al 65 performed multivariate analysis of various molecular markers in predicting recurrence or nonorgan-confined disease after RP. DNA ploidy or C-ERB-B2 immunohistochemistry predicted recurrence in logistic regression analysis. The C-ERB-B2 protein was also significant by univariate analysis for predicting progression of non-organ-confined disease. All of these studies have been hampered by small patient cohorts, variable antibodies for immunohistochemical detection of the oncoprotein and methodological variations in determining the degree of expression. C-ERB-B2 expression in PC does not seem to result from gene amplification. 64 This is important given the availability of efficacious treatments, which target C-ERB-B2 overexpression in breast cancer.
EZH2 polycomb oncogene
In carcinogenesis, large numbers of cancer-related genes can be switched on or off in a relatively short time. 66 . The polycomb group protein, 'enhancer of zeste homologue 2', is activated in advanced PC. EZH2 encodes the EZH2 protein, which is a known repressor of transcription.
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EZH2 causes generalised reduction in transcription in PC by increasing histone deacetylation via histone deacetylase-2. Varambally et al 12 found that EZH2 mRNA and protein are significantly increased in malignant PC compared to the benign prostate, and higher concentrations of EZH2 mRNA and protein in clinically localised PC predicts a poor prognosis. Repression of EZH2 by 12 Thus EZH2 appears to represent an exciting breakthrough as a marker of PC progression and metastasis.
RAF oncogenes RAF (regulator of alpha-fetoprotein) is involved in the regulation of alpha-fetoprotein (AFP) synthesis.
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Members of the RAF oncogene family encode serine/ threonine kinases, which activate the mitogen-activated MAPK or ERK kinases through direct phosphorylation. 69 The family of RAF-protein kinases consists of A-RAF, B-RAF, C-RAF 70 and d-RAF, a Drosophila homolog of the RAF proto-oncogene. 71 The binding of growth factors and matrix proteins to receptor tyrosine kinases and integrins, respectively, regulates several cytoplasmic signal transduction cascades, among which activation of the mitogen-activated protein kinase cascade, RAS-RAF-MEK-ERK, is perhaps the best characterised. 72 The RAF cytoplasmic serine/threonine kinases are regulated by binding RAS. 72 B-RAF somatic missense mutations were seen in 66% of malignant melanomas and at lower frequency in a wide range of human cancers. 13 All mutations were within the kinase domain, with a single substitution (V599E) accounting for 80%. Unfortunately, on analysis of three PC cell lines and genomic DNA from 23 PC patients, Davies et al 13 did not find any B-RAF mutations. Thus, larger cohort analyses for B-RAF mutation in PC are now required to come to a definitive conclusion on its role in this disease.
Treatment of human LNCaP cells with androgen or oestradiol triggers simultaneous association of androgen receptor or oestrogen receptor b with SRC, which activates the SRC/RAF/ERK-2 pathway and stimulates cell proliferation. 73 Basal phosphorylation of C-RAF, MEK1/2, MAPK and the transcription factor ELK-1 was significantly reduced by finasteride. 74 Antiproliferative and apoptotic effects of finasteride may be the consequence of this 74 and prostate epithelial apoptosis by finasteride may be useful in chemotherapy. PC with the RAS/MAPK pathway activated may have a selective growth advantage by autocrine TGF-b1 production. 75 C-RAF can prevent tumour cells from undergoing programmed cell death. This suggests that interference with C-RAF expression or function by specific drugs could represent a means for improving the efficacy of anticancer therapy. 76 
Tumour suppressor genes
The concept that TSGs exist and that their absence may induce the neoplastic state also developed in the 1970 s. [77] [78] [79] TSGs function in a recessive manner. If one copy of the gene is already missing because of an inherited defect, then loss of the sole remaining allele results in complete absence of that gene's product, which can lead to a cancer. The loss of both alleles of a gene, termed the 'two-hit' hypothesis by Knudson in 1971, 77 explained the epidemiology of retinoblastoma and loss of the RB gene was later confirmed to be causative [79] [80] [81] [82] ( Tables 3 and 4) .
Another well-characterised TSG is the P53 gene, the cause of Li-Fraumeni syndrome when absent in the germline. 83, 84 RB and P53 are implicated in many neoplasms as well as in these Mendelian cancer syndromes. 83 The WT gene in Wilms' tumour, VHL in van Hippel-Lindau syndrome, APC in colon carcinoma, NF-1 in neurofibromatosis and MEN (I and II) in tumours of the multiple endocrine neoplasia syndromes are other TSGs. [85] [86] [87] 'Gatekeeper' genes directly regulate the growth of tumours by inhibiting growth or promoting cell death. Each cell type has a few gatekeeper genes and inactivation of a given gatekeeper leads to a tissue-specific distribution of cancer. 88 Examples include APC in colon cancer and RB in retinoblastoma. Inactivation of these genes is rate limiting for tumour initiation. Where individuals inherit one mutant copy of a gatekeeper gene, tumour development requires only one additional somatic mutation, 77 and diseases penetrance is high. 'Caretaker' genes normally regulate genomic repair. Individuals with a hereditary mutation of a caretaker gene are at greater risk of developing tumours than the general population, but penetrance is not always 100%. Inactivation of caretaker genes does not promote tumour initiation directly but leads to genetic instability, which results in increased mutation rates of other genes, including critical gatekeepers. 89 In dominantly inherited cancer syndromes of the 'caretaker' type, patients inherit a single, mutant caretaker gene from an affected parent. Three subsequent somatic mutations are then required to initiate cancer: mutation of the normal caretaker allele inherited from the unaffected parent, followed by mutation of both alleles of a downstream gatekeeper gene. 90 The risk in these families is generally 5-50-fold greater than in the general population. 88 Caretaker genes include the HNPCC DNA repair genes, ATM, BRCA1 and BRCA2. Consistent with this hypothesis BRCA1 and 2 mutations are relatively rarely found in sporadic breast or ovarian tumours and the risks of cancer arising even with germline BRCA mutations are only about 70%. 89 
TSGs in prostate cancer
The quest to determine which TSGs are involved in PC has involved three approaches. The first was to study TSGs that had already been found to be important in other cancers, such as p53 and RB. 82 Secondly, a more specific approach has involved examining PC for regions of consistent chromosomal LOH, the rationale being that areas of genetic loss may mark the region of a prostate-specific TSG. 91 The third approach to the identification of PC TSGs involves linkage analysis in familial PC pedigrees and positional cloning. 92 Like the study of oncogenes, the study of TSGs in PC will provide insights into the malignant process and potentially generate both prognostic markers and future treatment strategies.
Retinoblastoma TSG
RB was the first identified TSG. 93 The RB gene is located on chromosome 13ql4 and the RB transcript is B4.7 kb in length. 94, 95 This 4.7 kb RB transcript codes for a 110 kDa nuclear phosphoprotein, which has DNA binding activity. 86 The RB gene product functions to suppress cell division by preventing cells in G1 phase from entering S phase. Retinoblastoma patients also develop other neoplasms, and the RB gene has been implicated in these and other cancers. 96, 97 Initial study of the RB gene in PC cell lines revealed the presence of abnormal RB protein in DU145, caused by a truncating mutation that resulted in a protein lacking 35 C-terminal amino acids. 98 Pidgeon et al. 99 analysed the PC cell lines, PC3 and DU-145, and found growth arrest was because of cell cycle inhibition at G0/ G1. This was associated with suppression of cyclin D1 and D3 levels. PC3 cells also showed a strong decrease in phosphorylated retinoblastoma protein, whereas retinoblastoma-associated proteins (p107 and p130), were inhibited in DU-145 cells. 99 Androgen-stimulated proliferation in the human PC cell line LNCaP is associated with reduced retinoblastoma protein expression. 100 Analysis of seven primary PC revealed absence or reduced expression of RB protein in two specimens. 101 One PC specimen lacking RB protein had a 103-bp (base pair) deletion in the RB gene at the transcriptional start site. Allelic losses of RB have also been reported in 11 of 47 patients in one study 98 and in 24 of 43 patients in another. 102 LOH at the RB locus occurred in 35% of the informative specimens and of the specimens that showed LOH, 33% also had decreased or absent RB protein in tumour cells by quantitative immunohistochemistry. 103 In contrast, none of the specimens without LOH showed loss of RB protein.
The most stringent test for a gene to qualify as a TSG is its ability to suppress the tumorigenic phenotype. The TSG is either introduced into tumour cells as a cloned cDNA in an appropriate expression vector 104 or as an individual chromosome by microcell-mediated transfer. 105 Introduction of a retroviral vector containing normal wild type RB cDNA into the PC cell line DU145 resulted in an approximately 15-fold reduction in the tumorigenicity of the transfectants in nude mice. 106 Also, the small tumours that did develop in nude mice lacked exogenous wild-type RB. A more comprehensive analysis of RB is needed in tumour specimens. This may be possible with the availability of antibodies for immunodetection of RB in paraffin sections 107 or by RB transcript analysis using an in situ PCR approach on tumour tissue sections.
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P53 TSG
Protein p53, named after the 53-kDa gene product, is a nuclear phosphoprotein 109 that can produce growth arrest at the G1-S checkpoint, allowing DNA repair. 110 Loss of this activity through mutation could produce genetic instability and allow metastatic progression. The wild-type p53 function may be lost when viral oncoproteins such as SV40 T-antigen, adenovirus E1B or human papilloma virus oncoprotein E6 bind and degrade it. 111 More classically it is inactivated by point mutations. 112 Wild-type p53 suppresses growth of human PC cells containing mutant p53 alleles, suggesting a functional role in suppressing prostatic tumorigenesis. 113 The p53 gene has been mapped to 17p13. 114 The short-arm of chromosome 17 is commonly deleted in human tumours and the remaining p53 allele frequently harbours point mutations. 84, 115 Germline mutations in the p53 gene have been described in rare cancer-prone families with Li-Fraumeni syndrome. 83, 116 Somatic mutations of the p53 gene have been reported in diverse neoplasms and, in fact, p53 mutations represent the most common genetic alterations (50%) in human cancers analysed. 117 p53 mutations have been commonly found in specific regions of the gene, in particular human tumours. 118 The main outcome of p53 activation appears to be growth suppression. However, many other functions have also been reported including roles in differentiation 119 and senescence. 120 Alternatively, normal p53 may suppress inappropriate angiogenesis through transcriptional regulation of fibroblast growth factor (FGF-2), 121 thrombospondin 122 and vascular endothelial growth factor. 122, 123 Normal p53 protein has a very short half-life within cells, whereas mutated p53 protein commonly has a prolonged half-life and is detectable by immunohistochemistry. 124 Another major function of p53 appears to be in mediating the cellular response to DNA damage and helping to maintain genomic stability. 125, 126 P53 is involved in the regulation of expression of genes induced during cell growth arrest triggered by DNA-damaging agents. 127, 128 Many forms of genotoxic stress, cause programmed cell death (apoptosis) and induce a rapid rise in p53 protein levels. This is achieved not only by stabilisation of normally short-lived p53 protein, but also by an increase in p53 mRNA levels. 129 When a cell encounters agents that cause DNA damage, p53 halts cell cycle progression by transcribing mitotic inhibitors including p21/Waf1 and GADD45. 130, 131 The CDK inhibitor p21/WAF1 binds to and inhibits cyclin kinase complexes, preventing phosphorylation of specific substrates and in turn the passage from G1 to S phases. 132 During this time the cell attempts to repair damaged DNA. 110 If the damage to DNA is irreparable, p53 triggers apoptosis. 133 If this regulatory function of p53 fails, cells with mutations in their DNA can progress through the cell cycle. For cell division to occur cells must enter the S phase and p53 cell growth arrest functions must be overridden. 112 Al-Maghrabi et al 134 found p53 immunoreactivity in 20% of PC foci, 17% high-grade prostate intraepithelial neoplasia and 0% benign epithelium, respectively. Reports of p53 alterations in PC specimens indicate that primary untreated PC has a lower degree of p53 activation than more advanced disease, ranging 137 Most studies report a range between 10% and 22% for p53 activation in primary tumours. [138] [139] [140] [141] [142] [143] [144] [145] Virtually, all investigators have detected more p53 activation in untreated metastatic 141, 144, 146, 147 than in treated metastatic 135 or hormone-refractory recurrent disease. 135, 140, 142, 144 In these tumours, the p53 activation rate ranges from 10% 147 to 80% 142 and appears to average from about 50% in untreated metastatic lymph nodes to approach 80% in hormone/radiation refractory disease. Navone et al, 148 found p53 mutations in PC bone metastases in up to 75% of cases.
Interestingly, one group of investigators has found p53 activation in BPH, 146 but others 138, 143, 149 have not confirmed this. The reason may be tumour cell heterogeneity. 150 There may be subsets of cells harbouring p53 mutations within a given tumour that are not detected because of the presence of normal stromal cells. 151 This question may require microdissection experiments for resolution. From a clinical standpoint, it will be very important to determine whether p53 activation is a useful tumour marker. For example, in the approximately 20% of patients who have p53 mutation in their primary untreated tumour, and for the 50-80% of patients with metastatic disease who have activation, is this an adverse prognostic marker? p53 protein expression is an independent prognostic marker for diseasefree survival after radical prostatectomy. 152 Furthermore, utilising an adenovirus vector to transfect normal p53 into PC cell lines, dramatic cell killing has been demonstrated. 153, 154 Phosphatase and tensin homologue TSG The gene PTEN (phosphatase and tensin homologue) or MMAC (mutated in multiple advanced cancers) is a TSG located at chromosome 10q23.3.
155-157 PTEN contains nine exons and encodes a 403 amino-acid, dualspecificity phosphatase with homology both to the protein tyrosine phosphatase family and to two cytoskeleton proteins, tensin and auxilin. Protein tyrosine phosphatases can act as either positive or negative regulators during signal transduction or cell transformation. 158 The homologue, tensin appears to bind actin filaments at focal adhesion complexes that contain integrins. Integrins are critical in cell growth regulation and tumour cell invasion. 159 Overexpression of PTEN arrests cell cycle progression in G1 and promotes anoikis. 160 PTEN is reportedly deleted and/or mutated in a significant fraction of breast, prostate and endometrial carcinomas, and also in glioblastomas and sporadic melanomas. 161 It has also been implicated in the autosomal dominant hamartomatous disordersCowden disease 162 and Bannayan-Zonana syndrome. 163 LOH and somatic mutation of PTEN are rare in early prostate carcinogenesis. 164, 165 Most mutations of PTEN were found in metastatic PC and were rare in localised tumours. 166 Only 5% of localised PC had complete inactivation of PTEN whereas over 30% of metastatic lymph node deposits had biallelic PTEN mutations. 166 Li et al 155 found PTEN mutation in 100% (4/4) of PC cell lines. LOH was also identified in 14% (6 of 44) of lymph node-negative and 43% (10 of 23) of lymph node-positive PC. This increase in genetic alterations in node-positive PC suggests that PTEN is a marker for metastatic progression. 167 McMenamin et al 168 found that complete PTEN loss correlates with high-stage and grade PC. Introduction of chromosome 10 fragments including the PTEN locus, by microcell-mediated chromosome transfer in AT6.3 (a highly metastatic Dunning rat PC cell line) produced a reduction in metastatic capability. 169 
Epithelial-Cadherin TSG
Cell adhesion molecules are cell surface proteins that play critical roles in cell recognition, contact inhibition and adhesion. These adhesion molecules, which include the cadherins, integrins, occludins, and a variety of immunoglobulin-like molecules, are essential for a wide variety of physiological processes such as epithelial barrier function and immune responses. 170 The classic cadherins are a group of calcium dependent, homophilic cellcell adhesion molecules that drive morphogenetic rearrangements and maintain the integrity of epithelial layers through the formation of adherens junctions. 171 E-cadherin, the prototypic member of the cadherin transmembrane protein family, regulates cell adhesion by interacting with E-cadherin molecules on opposing cell surfaces. 172 The cadherin-catenin complexes bind with intracellular actin, which results in stabilisation of cellular structure and tissue organisation. 173 Alterations of E-cadherin/catenin complexes are implicated in various steps of cancer development. This includes mutational inactivation, transcriptional downregulation of E-cadherin sometimes accompanied by upregulation of N-cadherin, proteolysis of E-cadherin and post-translational stabilisation of beta-catenin and plakoglobin. 174 Decreased expression of E-cadherin is seen in highgrade prostate tumours. There are frequent deletions in the region of chromosome 16q where the E-cadherin gene is located. 175, 176 Loss of E-cadherin function has been implicated in the pathogenesis of sporadic colorectal and other cancers. 177 Patients with germline mutation in the Ecadherin gene face a 70-80% likelihood of developing familial gastric cancer during their lifetime. 178 This risk is similar to the penetrance of MEN2 and BRCA1.
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Decreased E-cadherin expression was associated with an invasive phenotype of rat PC cells. 180 Taken together, these reports suggest that E-cadherin may function as a suppressor of the invasive phenotype in PC. The downregulation of E-cadherin is a feature of the metastatic phenotype, which may be a significant factor in the genesis of bone metastases. 181 The potential clinical relevance was emphasised in a study, which suggested that decreased E-cadherin expression correlated with stage and survival of PC patients. 182, 183 Patients who had recurrence after radical prostatectomy were significantly more likely to exhibit decreased E-cadherin expression. 184 Analysis of cadherin expression in premalignant lesions may provide additional diagnostic information to decide which patients need re-biopsy, more intensive monitoring or chemoprevention.
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BRCA1 and BRCA2 TSG Genetic linkage studies mapped a breast/ovarian cancer susceptibility gene to chromosome 17q12-21, 186,187 which led to the isolation and cloning of BRCA1.
188.
Almost
Molecular biology of prostate cancer MK Karayi and AF Markham simultaneously, linkage analysis localised a second breast cancer susceptibility locus BRCA2, at 13q12-13. 189 They are thought to be responsible for 80-85% of families with multiple cases of female breast cancer. 190, 191 Germline mutations of BRCA1 or BRCA2 account for 50% or 35% of the families with early onset breast cancer, respectively. BRCA1 and BRCA2 are also associated with PC [192] [193] [194] and pancreatic cancers. 190, 195 BRCA1 encodes an 1863-amino-acid 220-kDa nuclear phosphoprotein. 196, 197 BRCA2 has 27 exons and encodes a 3418-amino-acid protein. 198 The risk of getting ovarian or PC is less for BRCA2 than BRCA1 mutations. 199 A female BRCA1 carrier's risk of developing breast cancer by the age of 50 years is 60%, with a lifetime risk of 90%. 200 Studies from Iceland found that 44% of the fathers of patients with breast cancer and BRCA1 mutations had developed PC, 201 suggesting a role of BRCA1 mutation in PC. BRCA2 confers a high risk of breast and ovarian, but apparently a small risk of other cancers. 202 A study by Ford et al 203 calculated that the relative risk of PC given first-degree relatives with BRCA1 mutations was 3.3. Thus, BRCA genes are 'caretakers' rather than 'gatekeepers'. 88 Bennett et al, 192 also found an excess of male relatives with PC in a series of women with breast cancer. Anderson and Badzioch 204 stated that a family history of PC also increased the risk of breast cancer. Around 11% of women with breast cancer have a first-degree relative with PC. 193 The Utah Mormon database 205 was used for a large study, which showed the relative risk of developing PC if there is a family history of breast cancer, was 1.2. By comparison, the risk of developing PC if there is a positive family history of PC itself was 2.2. The risk increases with number and the degree of kinship of the affected relatives. In a study of Ashkenazi Jews, where over 2% carry mutations in BRCA1 or BRCA2, there was an elevated risk of PC as well as breast and ovarian cancer among carriers. 191 The above study also showed an increased frequency of other malignancies, including pancreatic cancer and lymphoma, in firstdegree relatives of patients with BRCA1 or BRCA2 mutations.
Several other studies of relatives of women with breast cancer have noted an increased incidence of both prostate and ovarian cancer. 192, 206, 207 The maximum relative risk cited of PC in BRCA carriers compared to the general population is 33.3. 203 The association of PC with other cancers is not straightforward, as some studies confirm it 190, 208, 209 and others do not. 210, 211 McCahy et al, 208 found an increase in breast cancer but no increase in ovarian cancer in relatives of PC probands. Introduction of 17q through microcell-mediated chromosome transfer has indicated a TSG for PC in a region of 28 cM (centi-Morgans) at 17q12-22 that includes BRCA1.
212 LOH at chromosome 17q shows an incidence of 16-44% in sporadic PC [213] [214] [215] and germline mutation of BRCA1 has also been detected in PC. 207 
RNASEL TSG
The RNASEL gene encodes a ribonuclease that mediates the antiviral and apoptotic activities of interferons through the (2-5)A system. 216 .
Germline variation in the RNASEL gene segregates in PC families that show linkage to the hereditary prostate cancer (HPC-1) region at 1q24-25. 92 In this case, RNASEL does not act as a 'classical' TSG. Here, possession of a 'high risk' allele simply predisposes to development of PC in the relatively large proportion of the population in which these occur.
RNASEL was identified by a positional candidate method. A nonsense mutation and an initiation codon mutation were found to segregate in two HPC1-linked families. 216 Inactive RNASEL alleles are present at a low frequency in the general population. 217 A total of six variants of RNASEL have been identified, including one intronic and five exonic changes (three missense and two silent alterations). The three missense polymorphisms (Ile97Leu, Arg462Gln, and Glu541Asp) were genotyped in 438 patients with familial PC and in 510 controls. Association testing revealed no significant differences between patients and control subjects for either the Leu97 variant or the Asp541 variant. However, significant differences were detected for the Arg462Gln genotype. 218 In subset analyses, associations were observed in the younger age group at PC diagnosis. The RNASEL variant may be the cause of a proportion of familial but not sporadic PC. 218 Analysis for RNASEL mutations was performed in 66 Finnish patients with HPC, 492 patients with unselected PC, 223 patients with benign prostatic hyperplasia and in 566 controls. Mutations were found in HPC families (9.5%) with four or more affected members. 216 Thus, the R462Q variant is associated with HPC in some families.
Rennert et al 219 identified a novel frameshift mutation in RNASEL, 471delAAAG, in Ashkenazi Jews. Casey et al 220 determined that the RNASEL variant R462Q has three times less enzymatic activity than the wild type and is significantly associated with PC risk (P ¼ 0.007). At least one copy of the 462Q allele was carried by nearly 60% of the men in families linked to HPC-1 in their study. Men who are heterozygous with respect to this variant allele had 50% greater risk of PC than noncarriers, and homozygotes had more than double that risk. Thus, germline mutations in RNASEL may be of diagnostic value, and the (2-5)A pathway might provide opportunities for developing therapies for those with PC. 217 Macrophage scavenger receptor TSG Macrophage scavenger receptor (MSR) gene expression is restricted to cells of monocyte origin and maximal during monocyte-to-macrophage differentiation. 221 MSRs are integral membrane proteins containing a collagen domain and exhibit a wide range of ligandbinding capabilities. 222 Deletions of human chromosome 8p22-23 in PC cells and linkage studies in families affected with HPC have implicated this region. 223, 224 The macrophage scavenger receptor 1 gene (MSR1, also known as SR-A) is located at 8p22. Genetic analyses of families affected with HPC, identified six rare missense mutations and one nonsense mutation in MSR1, which cosegregate with PC (P ¼ 0.0007). In addition, among men of European descent, MSR1 mutations were detected in 4.4% of individuals affected with sporadic PC as compared with 0.8% of unaffected men (P ¼ 0.009). Among African-American men, these values were 12.5 and 1.8%, respectively (P ¼ 0.01). These results show that MSR1 may be important in susceptibility to PC, in men of both African-American and European descent. 225 To further evaluate the role of MSR1 in PC susceptibility, five common variants of MSR1 were analysed in 301 patients with sporadic PC and 250 controls. Significantly different allele frequencies between cases and controls were observed for each of the five variants. 226 These results consistently suggest that MSR1 may play an important role in prostate carcinogenesis.
'Suppression of Tumorigenicity 7' TSG
LOH of markers on human chromosome 7q31 is frequently encountered in a variety of human neoplasia. By a combination of microcell-fusion and deletionmapping studies the TSG within 7q31.1-q31.2, named ST7 (suppression of tumorigenicity 7; also called RAY1) was identified. 227, 228 ST7 is ubiquitously expressed in human tissues. Analysis of a series of cell lines derived from breast and colon carcinomas revealed the presence of mutations in ST7. 229 Introduction of the ST7 cDNA into the prostate-cancer-derived cell line PC3 had no effect on the in vitro proliferation of the cells, but abrogated their in vivo tumorigenicity. 228, 229 The extent of its role in PC remains to be fully established.
Glutathione S-Transferase TSG Glutathione S-Transferase 1 (GSTP1), located at 11q13, belongs to the GST superfamily 230 that is involved in detoxification of electrophilic compounds by glutathione conjugation. 231 In addition, these enzymes play a role in the protection of DNA from oxidative damage. 232 Using methylation-specific PCR, Goessl et al 233 found that in 26 patients undergoing prostate biopsies for clinically suspected PC, all 10 patients diagnosed with adenocarcinoma (100%) and four of six patients with PIN (67%), but none of 10 patients with BPH (0%), exhibited GSTP1 promoter hypermethylation. Hypermethylation of the GSTP1 gene is the most common (490%) reported epigenetic alteration in PC. 234 Quantitation of GSTP1 hypermethylation accurately detects PC even in small tissue samples and as it occurs early in cancer progression it is a promising screening marker for detecting organ-confined disease. 234 The GSTP1 promoter is completely methylated in the LNCaP cell line, where this gene is transcriptionally inactive. 235 Treatment of LNCaP cells with a DNA methyltransferase inhibitor, decitabine (5-aza-2 0 -deoxycytidine) resulted in demethylation and activation of the GSTP1 gene. 235 Thibault et al 236 conducted a phase II trial using decitabine in patients with hormone-independent PC, with a modest clinical response in two of 12 patients.
'Kruppel-like factor 6' TSG Kruppel-like factor 6 (KLF6) is a ubiquitously expressed zinc-finger transcription factor gene, located at chromosome 10p15. 237, 238 Narla et al 239 analysed primary PC to find LOH at KLF6 in 77% of PC. In all, 71% of these showed inactivation in both KLF6 alleles, suggesting it to be a TSG. No mutation was identified in normal prostate tissue. Functional studies confirmed that whereas wildtype KLF6 upregulates p21 (WAF1/CIP1) in a p53-independent manner and significantly reduces cell proliferation, tumour-derived KLF6 mutants do not do so. 239 Recently, Chen et al 240 found much lower levels of KLF6 mutation: 15% in 93 PC patients. The majority of those with KLF6 mutations were of high grade and many were from metastases.
Metastasis suppressor genes
For a cancer to metastasise, cells must escape from the primary tumour, enter the circulation, arrest in the microcirculation, extravasate into a tissue compartment and acquire a new blood supply. 241 Metastasis suppressor genes prevent spread. Several groups have demonstrated that chromosomes 8, 10, 11 and 17 may encode PC metastasis suppressor activities (Table 5) . 169, [242] [243] [244] KAI-1 gene metastasis suppressor gene KAI-1 is for 'Kang ai', Chinese for anticancer. The KAI-1 gene on chromosome 11p11.2-13 has been suggested as a metastasis suppressor gene. 245, 246 It is expressed in most tissues but mainly in prostate, liver, kidney, bone marrow and placenta. 247 KAI-1 encodes a 2.4 kb mRNA for a membrane glycoprotein of 267 amino acids belonging to the TM4 superfamily, with four transmembrane domains and a large N-glycosylated motif. 248 This membrane localisation and extensive glycosylation suggest a function in cell-cell interactions and/or in cell-extracellular matrix binding, 247 both of which are important in invasion and metastasis.
KAI-1, when introduced into the highly metastatic Dunning R-3327 rat prostatic cancer subline AT6.1, significantly suppressed metastasis without affecting tumour growth rates. 243, 245 It does not suppress metastases in other highly metastatic sub-lines, for example, AT3.1.
249 KAI-1 expression is high in normal prostate and BPH but is lower in cancer cell lines derived from metastatic prostate tumours. KAI-1 protein is downregulated in metastatic PC compared to normal prostate and this downregulation does not commonly involve either mutation or allelic loss of the KAI-1 gene. 246 It could therefore involve epigenetic silencing by promoter methylation or via polycomb activation. 12 It has also been found that expression of KAI-1 correlated strongly with that of p53. Loss of these two markers resulted in poor survival. 250 Thus the loss of p53 function, which is commonly observed in many types of cancer, may lead to downregulation of KAI-1. This may ultimately result in metastasis. 250 Decreased expression of human KAI-1 is thought to be involved in the progression of PC and 
CD44 metastasis suppressor gene
The CD44 gene at 11p13, in the same region as KAI-1, has also been suggested as a metastasis suppressor. 249 Expression of this transmembrane glycoprotein is downregulated during PC progression this being correlated with higher tumour grade, aneuploidy and metastases. 249, 252 CD44 has several variant isoforms, standard (CD44s) and splice variants v3, v4/5, v6, v7/8, and v10. 253 The basal cells of the benign prostatic acini reveal uniform membranous staining for CD44s, v3 and v6 in 95-97% of cases. Similar staining was observed for v4/5, v7/8, and v10 in 40, 30, and 2% of cases, respectively. 254 The expression of CD44s, CD44v3 and CD44v6 is related to tumour differentiation. 253, 254 Downregulation of CD44s and its CD44v6 isoform is related to an unfavourable prognosis in PC. 253 In total, 60% of primary PC expresses CD44. There is an inverse correlation between histological differentiation (Gleason grade) and the expression of CD44. 255 Loss of CD44 expression is associated with increased grade and stage of PC. 256, 257 No metastases express CD44 strongly, and only 14% of metastases expressed even low levels of immunohistochemically detectable CD44. In nine of 11 lymph node metastases of PC, Verkaik et al 257, 258 demonstrated by methylation-sensitive restriction enzyme digestion that the promoter region of the CD44 gene is hypermethylated, indicating that this may represent a major mechanism of CD44 silencing. Transfection-induced expression of CD44 in the highly metastatic AT3.1 rat PC cell line greatly suppressed its metastatic ability to the lungs, without suppression of in vivo growth rate or primary tumorigenicity. 249 Decreased expression of CD44 is an independent prognostic marker for surgically treated PC.
259
NM23 metastasis suppressor gene NM23 encodes a nucleoside diphosphate kinase and maps to chromosome 17. This metastasis-suppressing protein 260 is implicated in PC. 261, 262 Increasing evidence suggests that the NM23 gene, initially documented as a suppressor of the invasive phenotype in some cancer types is involved in the control of normal proliferation and differentiation. 263 Low expression of NM23 has been correlated with poor prognosis and survival, lymph node infiltration and histopathological indicators of high metastatic potential, in a number of cancer types. 264 Loss of NM23 is an earlier event than the loss of E-cadherin, or abnormalities in p53. 265 In one study, analysis of NM23 expression by immunostaining revealed that its expression decreased significantly from BPH, PIN, through the PC stages, to cell lines. 266, 267 Another study found that, unlike breast cancer and melanoma in which decreased NM23 is associated with metastases, overexpression of the NM23 gene occurs frequently in adenocarcinoma of the prostate and may even be an early event of PC tumorigenesis. 268 Levels of NM23 mRNA and protein were both increased in metastatic PC lymph nodes compared to normal prostate tissue. Furthermore, cancer specimens and adjacent PIN showed immunoreactivity with NM23 antibody, but there was weak or no reactivity in normal prostatic tissue. 267, 268 More work is thus needed to clarify the role and clinical implications of NM23 in PC.
Mismatch repair genes
Microsatellites are highly polymorphic, repetitive di-, tri-or tetra-nucleotide sequences 269, 270 spread throughout the whole human genome. 271 Microsatellite instability (MSI) occurs where their length varies between tumour and normal DNA from the same patient. It is due to defective mismatch repair (MMR). 272, 273 MMR genes are responsible for coordinated correction of nucleotides mis-incorporated during replication. Inactivating mutations in MMR genes have been described in sporadic cancers and an hereditary cancer predisposition syndrome. 274 Thus, MMR deficiency particularly causes instability at microsatellites and increased mutation rates in general. 275 The MMR genes (hMLH1, hPMS1, hPMS2, hMSH2, hMSH3, hMSH6) generate mRNA transcripts in all PC cell lines. 276 MSI has been described in high-grade and lymph node positive PC specimens. An analysis comparing hMSH2 expression showed that in normal glands, hMSH2 staining was minimal to low and confined to the basal cell layer. In 32% of benign prostatic hyperplasia cases, hMSH2 staining was increased in the basal and luminal cell layers, whereas 71% of cancer specimens had uniform, moderate to strong staining. MSI was detected in 60% of specimens with absent to low hMSH2-staining and in 26% of moderate to high hMSH2-staining PC specimens. 275 The relative expression levels of hMSH2 and hMLH1 were significantly lower in cases than in controls (Po0.05 for both genes). When compared with controls, low expression levels of hMLH1 were associated with significantly increased risk of PC after adjustment for age, ethnicity, smoking status and family history of PC. 277 MSI has been documented in clinical PC specimens, at 19-65% for one or more loci, and at 12-44% for two or more loci. [278] [279] [280] In PC there is sometimes LOH 281 close to the hMSH2 locus, but MMR gene deletions are not yet confirmed in PC. These studies have shown that MSI in PC may be correlated with high-grade tumours in 65% 278 or 19.7% 279 of cases, respectively. Poorly differentiated PC (14.6%) showed MSI. 282 Extensive MSI occurred in 37.5% of highgrade tumours and advanced PC. 283 In another study 45% of tumours showed MSI but with no correlation to any stage or grade. 284 Cunningham et al 285 found 33% tumours with MSI and Watanabe et al 280 found 29% of prostate tumours had MSI. Yet another study found 35% MSI, without correlation to PC stage. 271 The above data suggest that genetic instability, as measured by MSI, occurs with high frequency in PC. It is possible that genetic instability in PC may therefore be due to mutations in hMSH2, hMLH1 and/or other genes involved in DNA repair pathways 286 or their epigenetic silencing by promoter methylation. 287 DNA repair gene activity is low in PC compared to normal prostate, 288 so that once mutations occur, they may accumulate faster in rapidly dividing neoplastic cells. 283 Prostate transitional zone and peripheral zone carcinomas display distinct and specific genetic alterations, which may explain the clinical differences between carcinomas arising in these distinct zones of the prostate. The above MMR phenotype may be linked to early development of transitional zone PC. 289 Wille et al 290 evaluated MSI as a marker to estimate the cancer risk in PC families. They studied seven first-degree relatives of PC probands and found 28% tumour MSI, suggesting that MSI is not more common when two first-degree relatives have PC than in sporadic PC. There was no correlation with tumour grade. In another study the most frequent locus (53%) altered by MSI was 10q23-24, 291 which is a common site of allelic loss in PC. 175 The frequency of MSI in latent cancer is lower than in clinical PC. 292 
Conclusions
The molecular biology of PC is still in its relative infancy and increasing our knowledge will require identification of more genes and their products contributing to PC carcinogenesis. Identifying the functions of these gene products and their cellular pathways will suggest better approaches to management of PC in the future and provide targets for new therapeutic agents. Recent insights gained from microarray studies 12 and genetic linkage studies in PC have restimulated interest in this essential activity.
